Illumina has agreed to acquire SomaLogic and related assets from Standard BioTools for up to $425 million, reinforcing its commitment to expanding proteomics capabilities and multiomics integration. This deal, including upfront and milestone payments plus royalties, consolidates a partnership dating to 2021 and brings SomaLogic’s DNA aptamer-based protein measurement technology under Illumina’s umbrella. The acquisition aims to accelerate the launch of Illumina’s Protein Prep assay and advance biomarker discovery leveraging next-generation sequencing platforms.